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Abstract
Many biologically active compounds, including macromolecules that are used as various kinds of drugs, must be 
delivered to the interior of cell or organelles such as mitochondria or nuclei to achieve a therapeutic effect. How-
ever, very often, lipophilic cell membrane is impermeable for these molecules. A new method in the transport 
of macromolecules through the cell membrane is the one based on utilizing cell-penetrating peptides (CPPs). 
Invented 25 years ago, CPPs are currently the subject of intensive research in many laboratories all over the 
world. CPPs are short compounds comprising up to 30 amino acid residues, which penetrate the cell membrane 
but do not cause cell damage. Additionally, CPPs can transfer hydrophilic molecules (peptides, proteins, nucleic 
acids) which exceed their mass, and for which the cell membrane is generally impermeable. In this review, we 
concentrate on the cellular uptake mechanism of CPPs and a method of conjunction of CPPs to the transported 
molecules. We also highlight the potential of CPPs in delivering various kinds of macromolecules into cells, 
including compounds of therapeutic interest. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 4, 257–269)
Key words: cell-penetrating peptides; membrane transduction peptides; covalent and noncovalent delivery 
strategy; endocytosis; anti-cancer drug delivery
Introduction
Because of the limitations of currently known drug de-
livery systems, mainly their low efficacy in overcoming 
the barrier of the cell membrane, there is a necessity 
to find new methods which efficiently and effectively 
increase the possibility of transport of protein mole-
cules into the cell interior. The main problem is the 
penetration of compounds into the lipophilic cell 
membrane as the hydrophobic nature of the plasma 
membrane results in its impermeability for the majo-
rity of hydrophilic, biologically active molecules. To 
overcome this problem, various techniques of cell 
membrane penetration, such as electroporation, mi-
croinjection, viral vectors, or liposomal encapsulation, 
have been proposed in recent years.
These methods, however, are not perfect, becau-
se of low efficiency of transport and cytotoxicity (to 
some extent). A method involving cell-penetrating 
peptides (CPPs) constitutes a new technique of cell 
membrane penetration based on the transport of ma-
cromolecules through the cell membrane. Due to the 
lack of permeability of cell membrane for hydrophilic 
biomolecules, the discovery of CPPs can be regarded 
as an important step forward in increasing the availa-
bility of therapeutically important substances such as 
peptides, proteins, or nucleic acids, however, of low 
membrane permeability.
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Definition and history of cell-penetrating 
peptides
Cell-penetrating peptides are short compounds, com-
prising up to 30 amino acid (aa) residues, which can 
penetrate the plasmalemma as well as mitochondrial 
and nuclear membranes, without causing any dama-
ge to the membranes [1]. CPPs were identified for 
the first time during the studies by two independent 
groups on the ability of cell penetration by HIV-1 
trans-activating protein Tat [2, 3]. They synthesized 
shorter analogs of 86-aa Tat protein, demonstrating 
a very high efficiency of penetration by Tat fragments 
of length between 21 and 48 aa or 58 aa. In 1991, 
Prochiantz et al. showed that synthetic 60-aa peptide 
(pAntp) corresponding to the Antennapedia homeo-
domain protein of Drosophila was internalized by 
nerve cells which resulted in morphological changes 
of neuronal cell cultures [4].
This finding served as the basis for obtaining the 
first CPP in 1994 — oligopeptide corresponding to 
C-terminal fragment of the third helix of the Antennapedia 
homeodomain consisted of 16 aa residues known as 
penetratin (RQIKIYFQNRRMKWKK) [5]. During 
the course of the experiments, it was noted that the 
reduction of oligopeptide length to 15 aa abolished its 
ability to penetrate into cells. Then, in 1998, Lebleu 
et al. identified the shortest Tat peptide sequence ne-
cessary for cell penetration — 47YGRKKRRQR [6]. 
Both of the abovementioned peptides correspond in 
their sequence to RNA/DNA-binding proteins. It was 
demonstrated that the transport of synthetic peptides 
was observed also at a temperature of approximately 
4°C, which, according to the authors, precluded endo-
cytosis as a mechanism of cell penetration [5, 6].
Depending on their chemical structure, CPPs may 
be amphipathic or may exhibit highly cationic proper-
ties and are usually rich in amino acids such as argi-
nine (Arg) and lysine (Lys). It has been proven that 
they are able to translocate various substances into the 
cells, including both low and high molecular weight 
molecules such as polysacharides, peptides, proteins, 
or nucleic acids [7]. The mechanism of penetration of 
CPPs into the cell membrane has not been completely 
understood. Previous studies reported different kinds 
of peptide transport depending on the class to which 
peptides belong to. Since their discovery, CPPs have 
been studied as carriers of many bioactive components 
penetrating cell membranes of different cell types [8].
CPP classification
Cell-penetrating peptides are currently classified in 
several ways, depending on their individual properties. 
In literature, instead of cell-penetrating peptides, 
terms such as ‘protein transduction domains’ (PTDs) 
and ‘membrane translocation sequence’ (MTS) are 
also used. CPPs can be classified by the functions 
of their original proteins, their uptake mechanisms, 
intracellularly evoked reactions, and their chemical 
properties. They can also be divided according to 
whether they are receptor-mediated or non-recep-
tor-mediated [9]. On the basis of their origin, CPPs 
can be classified into four groups: protein-derived 
CPPs, model peptides, chimeric CPPs, and synthetic 
CPPs. Protein-derived CPPs are usually short peptide 
sequences responsible for translocation, such as the 
Tat(47–57) fragment derived from the trans-activa-
ting protein. PTDs are primarily referred to Tat and 
penetratin.
Model peptides imitate the structure of the known 
CPPs — amphipathic MAP peptide, for example. 
Chimeric peptides are a combination of hydrophilic 
and hydrophobic peptide fragments of different ori-
gins. In this case, transportan (TP), a 27-aa long mole-
cule formed as a result of combination of galanin neu-
ropeptide and mastoparan, and its shorter 21-aa ana-
log, transportan 10 (TP10), are classic examples [10]. 
Peptides of polyarginine family belong to the group 
of synthetic CPPs [11].
CPPs can also be divided into three classes, in-
cluding different peptide sequences and lipid-binding 
properties as shown in Table 1. These groups are pri-
mary amphipathic peptides, secondary amphipathic 
peptides, and ‘non-amphipathic’ cationic peptides. 
Primary amphipathic CPPs (paCPPs) such as TP 
and TP10 usually consist of more than 20 aa residues 
and their primary structure contains hydrophilic and 
hydrophobic fragments. 
Previous studies indicated mechanisms of mem-
brane penetration by these peptides, along with the 
formation of pores, ‘carpet’ model, and inverted 
micelles in the membrane lipid bilayer [11]. In 
comparison with the primary peptides, secondary 
amphipathic peptides (saCPPs) such as penetratin, 
pVEC, and M918 contain fewer amino acid residues 
[5, 8, 12]. Their amphipathic properties are activa-
ted when a-helix or b-sheet is formed during the 
interaction with the membrane phospholipids [13]. 
Non-amphipathic peptides (naCPPs) are short and 
contain mainly cationic amino acids, e.g. Arg. Tat and 
Arg9 are, among others, included in naCPPs group 
[6, 14]. naCPPs and saCPPs are both less toxic than 
paCPPs, and higher concentrations or application of 
a transmembrane potential seems to be required to 
make the membrane unstable, both in the cell and in 
membrane model systems. It has been shown that acy-
lation of these cationic peptides to make them more 
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hydrophobic is a way to induce membrane leakage by 
this class of CPPs [13, 15]. The fourth class of CPPs 
are peptides derived from hydrophobic sequences of 
proteins which naturally interact with plasma mem-
brane, e.g. integrin b3-fragment [16], Hepatitis B 
virus translocation motif [17] or calcitonin fragment 
(Table 1) [18].
Cellular uptake mechanisms  
of cell-penetrating peptides
The mechanism of translocation through the cell 
membrane, despite some common features (e.g., total 
positive charge of the molecule) described for diffe-
rent CPPs, is different for each peptide depending 
on the class which a particular CPP belongs to. It 
has been observed that most CPPs may use different 
mechanisms of membrane translocation depending 
on the type and substitution position of a fluorophore 
as well as on the type of the transporting molecule. 
Molecular pathways of penetration and translocation 
across the cell membrane have not been still fully 
elucidated. Two major mechanisms of permeation 
through membranes have been proposed: direct 
membrane translocation without energy input and 
endocytosis.
Direct translocation
The results of internalization of CPPs into cells even 
at low temperatures excluded endocytosis as the main 
mechanism of transport of peptides into the cell and 
suggested the existence of an alternative mechanism 
which required no energy [19]. Such transport mecha-
nism was naturally observed for CPPs isolated from 
venoms: mastoparan [20] from V. lewisii wasp or cro-
tamine [21] from rattlesnake, which interact directly 
with cell membrane (Table 1). Other studies using 
peptides containing d-amino acids and peptides with 
retro-sequence showed similar (or better, in the case 
of d-amino acids) effectiveness as their equivalents 
containing l-amino acids or peptides with unmodified 
sequences, confirming the lack of receptor-specific 
endocytosis during cellular introduction [22, 23]. 
The concept of direct translocation requiring no 
energy input includes the evaluation of mechanisms 
observed with the contribution of inverted micelles, 
formation of pores, and the ‘carpet’ model [24, 25]. 
All these mechanisms are based primarily on the in-
teraction of positively charged CPPs with negatively 
charged components of the cell membrane such as 
heparan sulfate and phospholipid bilayer. This process 
requires permanent or temporary destabilization of 
the membrane caused by peptides present in the lipid 
layer of the membrane. Further internalization de-
pends on the concentration, the peptide’s amino acid 
sequence, and the lipid composition of the membrane 
as well. Direct translocation is most likely at high CPP 
concentration, in particular for primary amphipathic 
peptides such as TP and its analogs or MPGa peptide 
(Table 1) [26–28].
The mechanism involving inverted micelles is 
a model suggested for the direct transport of pene-
tratin [5]. This mechanism assumes local disorder of 
the phospholipid bilayer, resulting in the formation 
of inverted hexagonal structures (inverted micelles). 
It was found that peptides are encapsulated in the 
hydrophilic environment of micelle interior until the 
reverse process resulting in the destabilization of the 
inverted micelle occurs, and, consequently, a peptide 
is released into the cell interior. This was confirmed by 
the results obtained from experiments using nuclear 
magnetic resonance (NMR) [29]. This mechanism is 
driven mainly by the CPP gradients on both sides of 
the cell membrane [30].
The ‘carpet’ model explains the possibility of inter-
nalization of small hydrophilic peptides. Additionally, 
despite the interactions between positively charged 
CPP components and negatively charged lipid mem-
brane components, hydrophobic amino acid residues 
such as tryptophan, along with hydrophobic elements 
of the membrane, are also involved in this mechanism. 
Therefore, this kind of cell membrane penetration 
and delivery of molecules are less likely for strongly 
cationic peptides such as Tat, Arg8 or Lys8 [31]. Expe-
riments using NMR and electron microscopy revealed 
the formation of other structures than inverted micel-
les when Tat, Arg8, or Lys8 were used [32].
Analogous to the mechanism of membrane struc-
ture disorder resulting in the formation of inverted 
micelles observed during internalization of peptides 
and toxins, alternative mechanisms of CPP translo-
cation were also proposed. Hence, the mechanism of 
penetration into the cell membrane involving pore 
formation includes two models — ‘barrel-stave’ mo-
del and ‘toroidal’ model. In the ‘barrel-stave’ model, 
peptides possessing the structure of a-helix form 
a bundle in the membrane with a channel at its center. 
It resembles a barrel constructed of staves. The staves 
are CPPs’ fragments inserted into membrane. Hydro-
phobic regions of the helix are localized in the region 
of the membrane lipids. In addition, the hydrophilic 
region of CPP is bound to the hydrophilic heads of 
phospholipids forming an inner part of a gap.
In the ‘toroidal’ model of pore formation, peptides 
penetrate into the lipid bilayer of the membrane and 
cause bending of the lipid monolayer into the interior 
forming a hydrophilic gap in plasma membrane. In 
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Table 1. Classification of CPPs according to their origin and biochemical properties according to Reissmann [9]
CPP  
classification
CPP name Amino acid sequence Amino 
acid  
length
According to origin
Peptides derived from protein transduction domains
HIV Tat(47–57) YGRKKRRQRRR 11
Penetratin RQIKIWFQNRRMKWKK 16
Transportan (TP) GWTLNSAGYLLGKINLKALAALAKKIL 27
VP-22 DAATATRGRSAASRPTERPRARARSASRPRRPVD 34
Ligands for the subfamily of integrins
RGD peptides avb3 RGD-Temporin-LA, RGD-Dye
RGD peptide Cyclo(RGDfK); cyclo(RGDyK)
Venoms and toxins
Mastoparan INLKALAALAKKIL-amide 14
Mellitin GIGAVLKVLTTGLPALISWIKRKRQQ-amide 26
Rattle snake toxin (Crotamine) 
derived NrTP6
YKQSHKKGGKKGSG 14
Histones and histidine peptides
H1, H2A, H2B, H3, H4 Single histones or mixtures of them
Histidine-rich CPP HR9: C-HHHHH-RRRRRRRRR-HHHHH-C
Partial sequences of tumor selective enzyme
Redox protein azurin ‘p18’ Azurin Leu50–Gly67: LSTAADMQGVVTDMGASG 18
Bacterial Peptides
Bac7 (1–35) RRIRPRPRLPRPRPRPLPFPRGPRPIPRPLPFP 33
Bac7 (5–35) PRPRLPRPRPRPRPLPFPRGPRPIPRPLPFP 31
According to chemical structure
Amphipathic peptides
Transportan 10 (TP10) AGYLLGKINLKALAALAKKIL-amide 21
Pep-1 Ac-KETWWETWWTEWSQPKKKRKV-NH-CH2-CH2-SH 21
MPGa Ac-GALFLAFLAAALSLMGLWSQPKKKRKV-NH-CH-
2-CH2-SH
27
CADY Ac-GLWRALWRLLRSLWRLLWKA-NH-CH2-CH2-SH 20
Pepfect6 Stearyl-AGYLLGK(e-TMQ)INLKALAALAKKIL 21
MAP KALAKALAKALA 12
KLA sequence Acetyl-KLALKLALKALKAALKLA-amide 18
Cationic peptides
Oligoarginines (Arg9–Arg12) RRRRRRRRR - RRRRRRRRRRRR 9–12
HIV Tat(47–57) YGRKKRRQRRR 11
Penetratin RQIKIWFQNRRMKWKK 16
FHV coat (35–49) RRRRNRTRRNRRRVR-amide 15
Chimeric dermaseptin S4 and SV40 
‘S413-PV’
ALWKTLLKKVLKAPKKKRKVC 21
Herpes simplex virus transcription 
factor (267–300) VP22
DAATATRGRSAASRPTERPRAPARSASRPRRPVE 34
Hydrophobic peptides
Kaposis sarcoma fibroblast growth 
factor Kaposi FGF
AAVALLPAVLLALLAP 16
Signal sequence of Ig light chain 
from Caiiman crocodylus
MGLGLHLLVLAAALQGAMGLGLHLLLAAALQGA 33
Integrin b3-fragment VTVLAGALAGVGVG 14
Fusion sequence HIV-1 gp41(1–23) GALFLGFLGAAGSTMGA 17
Hepatitis B virus translocation motif PLSSIFSRIGDP 12
Human calcitonin partial sequence 
9-32, hCT(9-32)-br
LGTYTQDFNK(X)FHTFPQTAIGVGAP-amide
X: PKKKRKVEDPGVGFA
41
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the gap, phospholipids’ heads and peptides are found. 
CPPs involved in this model of cellular introduction, 
demonstrate the possibility of a-helix structure for-
mation. TP and mastoparan exhibit lytic and antimi-
crobial properties [33, 34] and by the formation of 
a pore, they cause leakage of protons, metal ions, and 
proteins, which results in cell death. In the ‘toroidal’ 
model, polar peptide fragments are bound to the polar 
heads of phospholipid groups, as shown in Figure 1. 
This model is different from the ‘barrel-stave’ model 
in that the peptides are always bound to phospholipid 
heads, even during penetration through the lipid layer.
In both models, pores are formed when the con-
centration of the peptide exceeds a threshold value 
which varies depending on the CPP [35, 36]. In the 
‘toroidal’ model, pore diameter is also important; for 
example, in case of mastoparan the translocation of 
particles sized < 1000 Da into the cell interior was 
observed [25]. Due to pore formation, amphipathic 
CPPs are more cytotoxic in comparison to peptides 
that act according to other mechanisms of cell pene-
tration, such as penetratin or oligo-arginine [37, 38].
In the ‘carpet’ or adaptive translocation model, 
peptides do not penetrate into the lipid bilayer, but 
accumulate on its surface. They are electrostatically 
bound to the hydrophilic heads of phospholipid mole-
cules in many locations, covering the surface of the cell 
membrane. Such ‘carpet’ arrangement of peptides on 
the surface of the membrane causes its destabilization. 
The interactions between negatively charged phospho-
lipids and cationic CPPs induce covering of the cell 
membrane by CPPs and its further thinning. When the 
concentration of the peptide exceeds a threshold va-
lue, translocation of CPP is observed [38]. Arg9, which 
exhibits over a hundred times higher translocation 
efficiency in comparison to the corresponding peptides 
His9, Lys9, and deca-ornithine, mainly participates in 
the adaptive translocation model [22, 39].
The important role of the guanidine group of Arg 
was also confirmed via the analysis of penetration of 
synthetic oligomers of Arg composed of d-amino acids 
or polyguanidine peptoids containing at least seven 
guanidine groups [22]. It has been suggested that Tat 
also penetrates into the cell according to the ‘carpet’ 
model, which is related to the presence of guanidine 
groups including CPP, as well as interactions between 
Tat and phosphate groups of phospholipid bilayer 
[22, 40]. The membrane potential serves as a driving 
mechanism in the ‘carpet’ model. The inhibition of 
Arg9 penetration through cell membranes was ob-
served after incubation of cells in a buffer containing 
isotonic concentration of K+ ions [41]. Furthermore, 
the addition of valinomycin, an antibiotic increasing 
membrane potential, resulted in a significant increase 
of Arg8 penetration [42].
Despite the common features of the presented 
models of direct translocation, attention should be 
paid to the different elements of these mechanisms:
— The model of the inverted micelle assumes no 
direct contact between the peptide and the hy-
drophobic components of phospholipids, which is 
observed for the other modes of transport without 
energy contribution, in which the formation of 
membrane pores by a change in the conformation 
of membrane phospholipids occurs.
— The ‘toroidal’ and ‘carpet’ models assume a signi-
ficant reorganization of membrane phospholipids, 
as opposed to the ‘barrel-stave’ model, where no 
such significant changes across the membrane are 
observed.
— In the inverted cell model, interactions between 
CPPs and cell membranes result in the formation 
Figure 1. Proposed mechanisms of direct translocation of CPP through the cell membrane as proposed by Trabulo et al. [19]
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of concave fragments of the membrane, and in the 
‘toroidal’ model, membrane protrusions occur.
— In the ‘barrel-stave’ and ‘toroidal’ models, forma-
tion of pores within the membrane, through the 
homo-oligomerization of peptides introduced in 
the membrane, allows the prediction of well-de-
fined structures, unlike the highly unpredictable 
and variable elements constituting the ‘carpet’ 
model [19]. 
— The driving forces of the direct translocation pro-
cesses are CPP gradient for the ‘toroidal’ model 
and the inverted micelle or membrane potential 
in case of adaptive translocation model.
All models of direct translocation, except for the 
inverted micelle model, allow the transfer of large-sized 
particles. In addition, these models require the presence 
of secondary structures composed of a-helices, which are 
part of many CPPs. However, regardless of the model, 
the translocation of large molecules requires a large 
destabilization of cell membrane, which is not correlated 
with the observed low cytotoxicity of CPPs and their 
conjugates. Thus, none of the presented models can fully 
explain the results of experiments with different CPPs, 
suggesting a contribution of alternative mechanisms of 
peptides’ internalization, especially during penetration 
combined with molecular delivery [19].
Energy-dependent endocytosis-mediated  
cellular uptake
Despite the fact that results of many studies have shown 
the contribution of endocytosis in the CPP internalization 
mechanism and their cargo molecules, there are contro-
versies surrounding the exact definition of the type of 
endocytosis involved in this process (Figure 2) [19]. Hen-
ce, cell biology techniques were used to determine the 
type of endocytosis contribution or the transport without 
energy contribution in the process of CPP absorption:
— incubation of cells with CPPs at low temperatures 
(< 4°C) or under energy deficiency;
— application of trypsin to remove surface receptor 
proteins;
— use of confocal or freeze-fracture electron micro-
scopy [43, 44];
— incubation with compounds facilitating selective 
transport pathway, e.g. brefeldin A [45];
— binding to a cargo molecule determining a specific 
type of transport (e.g. transferrin, cholera toxin, 
dextran, or G protein) or to the target location 
in the cell allowing the determination of interna-
lization type (e.g. caveolin-1 endosome antigen 
1 EEA1) [46];
— overexpression of mutant genes of proteins associa-
ted with appropriate models of internalization (e.g. 
dynamins), which led to the exclusion of a strictly 
defined process from further investigations [19].
The abovementioned methods enable a more 
accurate determination of the complexity of the 
mechanisms of CPP transport into cells, depending 
on the amino acids sequence. It was demonstrated 
that the fusion peptide GST-Tat-GFP is subjected to 
internalization during caveolin-dependent endocyto - 
sis [47]. On the other hand, macropinocytosis, as one 
of the main endocytosis pathways that accompanies 
cell surface ruffling, was found to be the mode of CPPs 
cellular introduction as shown by numerous studies 
[48]. In turn, the native Tat protein (9837 Da), Tat 
PTD (1000–5000 Da) and Tat-HA2 fusion protein 
Figure 2. Proposed mechanisms of CPP translocation by endocytosis as proposed by Trabulo et al. [19]
263Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.a2014.0034
www.fhc.viamedica.pl
(> 30,000 Da) are introduced into the cells mainly by 
macropinocytosis [49, 50]. On the contrary, the results 
of the studies conducted by Richard et al. involving 
native Tat protein have led to the observation of in-
ternalization by clathrin-coated vesicles [51]. 
With respect to cell-penetrating peptides, it has 
been demonstrated that the penetration of Arg9 mo-
del peptide and other oligomers of arginine into the 
cell occurs via endocytosis dependent on the peptide 
binding to the membrane-specific heparan sulfate. 
Subsequently, inside endosomal vesicle, heparan sul-
fate may be degraded by heparanase, which leads to 
the dissociation of peptides, and, consequently, to the 
interaction of CPPs with the endosomal membrane. 
Finally, after destabilization of endosomal membrane, 
the peptides are released into the cytoplasm [52]. 
Thermodynamic studies have shown that paCPPs 
and saCPPs can penetrate into the cell interior thanks 
to the direct translocation at low, micromolar con-
centrations. In turn, naCPPs also penetrate the cell 
membrane at low concentrations as a result of the 
endocytosis [38]. However, it should be noted that 
depending on the experimental conditions, different 
mechanisms of translocation through the membrane 
has been reported for all CPPs.
The discrepancies between results obtained by 
various groups may partially result from the use of 
various concentrations of CPPs in different biological 
(i.e. cellular) models, which may cause the induction 
of different transportation pathways, involving the 
pathway which requires no energy input, as well as 
different types of endocytosis. Thus, for instance, 
higher concentrations of CPPs (> 10 µM) may lead 
to direct translocation [27, 53, 54]. Until one of the 
methods of cell membrane penetration is not consi-
dered to be the most dominant and reliable, it can be 
assumed that each of the above-described transport 
pathways may be involved in the penetration of CPPs 
depending on their concentration, hydrophobicity, or 
other physicochemical parameters. The method of 
CPP penetration into cells can also be affected by the 
charge type, the class of CPP, the cell line used in the 
experiment, and incubation conditions [55].
Different pathways of cellular introduction also 
depend on a cargo molecule. It was noted, that micropi-
nocytosis is the mechanism of penetratin transport if it is 
conjugated with dextran [56], whereas lipid raft-mediated 
endocytosis and direct translocation are involved when 
PLA-PEG (polylactic acid-polyethylene glycol) was the 
cargo of penetratin [57]. Additional examples of cargo-
mediated transport pathways are presented in Table 2.
Methods of CPP conjugation  
with transported molecules
Binding of CPPs with transported molecules may 
occur in different manners, most often by covalent 
bonds. In case of peptides or proteins, there is a direct 
binding between the transported molecule and CPP. 
In other cases, the use of a special linkage, the so-cal-
led linker, is recommended. The appropriate linker 
should be characterized by as low toxicity as possible 
and the ease of molecule release from the CPP after 
crossing the cell membrane. The role of the linker is 
often attributed to side chains of the residues present 
in CPP amino acid sequence, such as the thiol group of 
cysteine or the e-amino group of lysine. Non-covalent 
interactions, such as between streptavidin and biotin 
attached to CPP, are also possible [45].
Covalent strategy
Introduction techniques using CPPs are mainly ba-
sed on the formation of covalent bonds between the 
Table 2. Types of CPPs cellular introduction with cargo according to Farkhani et al. [103]
Peptide Cargo Proposed uptake mechanisms
Penetratin Dextran Macropinocytosis
PLA-PEG Lipid raft-mediated endocytosis and direct translocation
Tat QDs Macropinocytosis
Liposomes Endocytic uptake through binding to HSPGs
Liposomes Endocytic uptake
SPIONs Endocytosis
Gold nanostars Actin-driven lipid raft-mediated macropinocytosis
Arg8 Liposomes
Vesicular transport
Macropinocytosis
PLA-PEG — polylactic acid-polyethylene glycol; QDs — quantum dots; SPIONs — superparamagnetic iron oxide nanoparticles; PNA — peptide nucleic acid
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peptide and the molecule transported. The bond is 
formed by chemical binding with linker or by cloning, 
after which the expression of protein-bound CPP is 
observed [58–60]. Most studies describe the following 
protein-derived peptides and their derivatives used in 
covalent binding to the cargo molecule: Tat, penetra-
tin, Arg8 and TP [6, 14, 61, 62].
Other protein-derived peptides such as VP22 pro-
tein from herpes simplex virus, pVec, calcitonin-deri-
ved peptides, and antimicrobial peptides buforin I and 
SynB peptide have also found an application in order 
to confirm the possibility of transport of various che-
mical compounds covalently bound to peptides [1, 4]. 
In addition, CPPs of new generation containing diffe-
rent motifs or transduction domains in combination 
with protein or oligonucleotide-binding domains have 
been developed [63, 64]. 
Disulfide and thioester bonds are mainly applied. 
The results of the studies suggest the possibility of 
application of covalent bonds for the delivery of pep-
tide nucleic acid (PNA), PMO oligomers, peptides, 
and proteins [65]. The use of covalent binding has its 
certain advantages and disadvantages as well. The 
positive aspect of this method is the improvement 
and reproducibility of the procedures along with the 
control of stechiometry provided by CPP molecules.
However, from a chemical viewpoint, covalent bin-
ding of CPP to the delivered molecules is limited and 
also carries the risk of changes of biological activity of the 
molecules transported. In the case of oligonucleotides or 
siRNA transporting, binding to CPP may lead to the re-
duction of their biological properties, and therefore the 
use of noncovalent bonds may be more appropriate [65].
Noncovalent strategy
Binding of CPP with transported molecules by non-
covalent bonds is mainly based on short amphipathic 
peptides consisting of two domains, hydrophilic polar 
and hydrophobic nonpolar. These peptides include 
MPG, Pep-1, MAP, SAP, and PPTG1 (see Table 1). 
Their amphipathic character may result from primary or 
secondary structure. Primary amphipathic peptides can 
be described as sequentially arranged subsets of domains 
of hydrophobic and hydrophilic residues. Secondary 
peptides are formed due to the conformation that ena-
bles the arrangement of hydrophobic and hydrophilic 
residues on opposite sides of the molecule [66].
The group of primary amphipathic peptides in-
cludes MPG and Pep-1, which contain a hydrophilic 
domain rich in lysine residues derived from nuclear 
localization signal (NLS) sequence of the SV40 virus 
protein. Apart from this sequence, MPG also in-
cludes the N-terminal hydrophobic fragment derived 
from the gp41 of HIV protein, and the composition 
of Pep-1 includes the hydrophobic domain rich 
in tryptophan residues. For the abovementioned 
CPPs, both domains are connected with the domain 
linker providing the flexibility and cohesion between 
the hydrophobic and hydrophilic parts. MPG and 
Pep-1 form stable complexes with the transported 
molecules such as oligonucleotides, peptides, and 
proteins, via noncovalent electrostatic and hydro-
phobic interactions.
The efficacy of the amphipathic Pep-1 peptide in 
the efficient delivery of noncovalently bound pep-
tides and proteins was demonstrated [67]. Nonco-
valent bonds were effective also in the case of MPG 
transferring siRNA into cells [68, 69]. Moreover, the 
effectiveness of noncovalent bonds for such CPPs as 
Tat, polyarginine, TP (and its derivatives) transporting 
proteins or oligonucleotides has been proven [62, 64]. 
Examples of CPP and methods of their conjugation 
with transported molecules were shown in Table 3.
Influence of CPPs on cells and at body’s level
CPP cytotoxicity in vitro
The vast majority of studies on the toxicity of CPPs 
using human/mammalian cells refer to in vitro stu- 
dies [70]. Comparative studies confirm the differences 
between cytotoxicity depending on the composition 
and classification of the CPPs. Thus, disruption of 
the integrity of the cell membrane — manifested by 
leakage of cytoplasmic components — by amphipathic 
CPPs has been correlated with their hydrophobic 
potential [71]. Analysis of the cytotoxicity of unmodi-
fied CPP by the measurements of a cytosolic enzyme 
lactate dehydrogenase (LDH) leakage, membrane 
depolarization with the use of DiBAC4(3), MTT test, 
and the analysis of hemolysis showed relatively high 
cytotoxic properties of TP10 as a model amphipathic 
CPP and the average cytotoxicity of CPP representa-
tives rich in arginine, such as Tat and penetratin [72].
In turn, studies on synthetic CPPs such as oligo
-Arg, performed on mouse myoblasts showed the 
least, both short- and long-term, cytotoxic properties 
of Arg9 [70]. Hence, in the case of CPPs, decreasing 
sequence-dependent cytotoxicity has been postulated 
in an order: oligo-Arg > penetratin > Tat [73, 74]. 
For TP10, the analysis of toxicity provided different 
results depending on the type of cell used: cervical 
cancer HeLa cell line was very sensitive and fibroblast 
cell line NIH 3T3 was relatively insensitive to the 
doses up to 25 µM [10]. It was also observed that in 
vitro cytotoxicity of CPP changes significantly after the 
binding of transported molecules such as fluorescent 
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labels or other proteins [73]. For example, the toxi-
city of Tat fusion protein with anti-apoptotic NEMO 
(NF-kappaB essential modulator) domain is increased 
more than a hundredfold [75]. It has been proposed 
that binding macromolecules to CPP changes — due 
to the size of the complex — the mechanism of CPP 
internalization from direct translocation to endocy-
tosis, which is related to the lower number of CPPs in 
a cell and thus lower cytotoxicity [70, 74, 76]. 
Another goal of the in vitro studies is the selective 
binding of CPPs by different types of cells, especially, 
cancer cells. It was noted that due to the overexpres-
sion of CXCR4 receptor on cancer cells, CXCR4 
receptor binding partner — Arg12 — showed high 
efficiency of penetration into tumor cells [9, 77]. 
The most recent reports have suggested the selective 
uptake of azurin-based CPPs by breast cancer [78], 
melanoma [79] or lymphoma [80, 81] cells in vitro.
In vivo studies of CPPs
Similarly as for the in vitro studies, results of CPP 
toxicity measured in vivo are difficult to compare due 
to methodological differences: type of animal, route 
of administration, methods for determination of bio-
logical effects, the type of molecules transported, and 
the type of CPP [70]. For instance, Tat and penetra-
tin conjugated with the siRNA of p38 gene, inhaled 
by laboratory mice, caused a transient decrease in 
the expression of p38 MAP kinase gene, which was 
observed mainly in lung macrophages and adjacent 
pneumocytes [82]. In Sprague Dawley rats, after 
intravenous administration of RXR4 fusion peptide 
(X = 6-aminocaproic acid) was bound to PMO (pho-
sphorodiamidate morpholino oligomer), a threshold 
below 15 mg/kg was established at which fusion CPP 
was not toxic, whereas the dose of 150 mg/kg was 
associated with adverse side effects such as lethargy, 
weight loss, and elevated serum creatinine [83]. 
Based on clinical and histological observations 
in BALB/c nu/nu knockout mice transplanted with 
pancreatic metastatic tumor cells, intravenous admi-
nistration of a fusion CPP, penetratin-Grb7 peptide 
inhibitor at a maximum dose of 100 mM/kg every 
three days was recommended due to lack of toxicity 
at body’s level [84]. In mice with colorectal tumors 
Table 3. Examples of CPP and methods of their conjugation with transported molecules according to Kilk [104]
Peptide Cargo type Specification of cargo Type of connection Ratio CPP/ 
/cargo
Penetratin Low molecular weight compound Fluorophore Covalent 1
TP10 Peptide PKC Disulphide 1
pTat Peptide PKC Disulphide 1
pTat, Penetratin Peptide Cyclin, cyclin-dependent 
kinase inhibitors
Synthesis from one 
mRNA
1
pTat, Arg11
Arg9, Arg7
Protein EGFP Fusion 1
Pep-1 Protein GFP, Pep-A Non-covalent 6–8 for Pep-A
12–14 for GFP
pTat and Penetratin Protein Avidin Biotin-avidin 1 (4)
Arg8 Protein Proapoptotic protein + 
EGFP with His tail
Ni2+ – His  
(non-covalent)
1
Penetratin Oligonucleotide Nonsense PNA Peptide bond 1
TP Oligonucleotide PNA for chromosome X Disulphide 1
pTat Polyanion DNA, heparan sulfate Interaction  
between charges
> 7
TP, TP10 Oligonucleotide Target sequence for NF
-kappaB
Thiol to PNA, 
hybridization 
between PNA- 
-oligonucleotide
1
TP Colloidal gold Covalent complex  
gold-avidin
Biotin-avidin 1 (4)
pTat, longer version of NLS Virus Lambda phage Expression on 
phage surface
ND
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derived from transplanted human HCT116 cells, after 
injection of DA3-PEI fusion CPP conjugated with 
siRNA for XIAP mRNA (overexpression of XIAP 
was frequently noted in various types of cancer [85]), 
a significant reduction in tumor size was observed [86]. 
Recently, in vivo studies with the administration of 
morpholino oligos conjugated with CPPs are carried 
out, since they were shown to efficiently block or 
repair the expression of targeted genes. Morpholinos- 
-CPPs showed efficient splice correction-therapy in 
Duchenne muscular dystrophy [87] (Table 4). Studies 
with the use of morpholinos-M12 (muscle-homing 
CPP) showed in about 25% of mdx deficient mice nor-
mal level of dystrophin, suggesting that M12 CPP can 
be efficiently used in lower than 75 mg/kg doses [88].
Another goal of CPP usage in modern medicine 
is vaccination. Administration of vaccines or pharma-
ceutical agents in lower concentrations in assistance 
of (or fused with) CPPs, was noted as a promising 
opportunity [89]. Although none of the vaccines 
conjugated with CPPs have passed the FDA thre-
shold into the clinics, there are numerous ongoing 
preclinical and clinical evaluations of them [90]. The 
first CPP-pharmaceutical agent conjugate, cyclospori-
ne-Arg8 (PsorBan
® by Cell Gate Inc., Redwood City, 
CA, USA) passed clinical tests and was used for the 
topical therapy of psoriasis by transdermal delivery of 
cyclosporine A [91]. The conjugate entered Phase II 
clinical trial, which was eventually terminated in 2003. 
The modern CPP-vaccines were tested for myocar-
dial infarction [92], spinal cord injury [93] and HIV 
vaccination. Other studies have been re performed in 
metastatic solid tumors [89] or in acute sensorineural 
hearing loss caused by cochlear injury [94]. Examples 
of CPPs conjugated with pharmaceutical agents in 
clinical development are shown in Table 4 [89].
CPPs were recently used for the introduction of 
active agents across blood-brain barrier (BBB) [95], 
which is normally impermeable for most of the phar-
maceutical substances at non-toxic concentrations [96]. 
For protein introduction, administration of Tat-JNKI1 
fusion protein 3 hours after brain ischemia significan-
tly reduced the infarct volume in mice [97]. SOCS3 
protein introduced with FGF4-CPP protected mice 
from lethal effects of staphylococcal enterotoxin B 
and lipopolysaccharide by reducing production of 
inflammatory cytokines and hemorrhagic necrosis in 
brain [98]. In experiments with human patients with 
brain metastases, efficient introduction of anti-cancer 
drug, paclitaxel, was observed when conjugated to An-
giopep-2 CPP [99]; significant uptake of doxorubicin 
was noted when the drug was conjugated either with 
Angiopep-5 [100] or SynB1/SynB5 CPPs [95, 101]. 
It was noted that most cancer cells isolated from 
metastases are characterized by multidrug resistance. 
Therefore the efficient delivery of cytotoxic agents 
into those cells is highly required [102]. The studies of 
CCPs usage in the administration of anti-cancer drugs 
such as doxorubicin, paclitaxel, vincristine sulfate 
and taxol have been well-established recently [103]. 
Doxorubicin was conjugated to Tat, penetratin and 
Arg8 derivatives, whereas paclitaxel and taxol where 
connected to either Tatp-Cys or Arg8, respectively. 
The examples of in vivo studies of CPP-anticancer 
drug delivery have been presented by Farkhani et al. 
in a recent review [103].
Table 4. Examples of clinical studies of the CPP conjugates usage, modified from the review by Shi et al. [89]
Conjugate CPP Cargo Disease Clinical phase (years)
PsorBan Arg8 Cyclosporine A Psoriasis Phase II terminated (2003)
RT-001 Lysine-rich peptides sandwiched 
by two Tat(49–57)
Botulinum toxin type A Lateral canthal lines, 
crow’s feet and facial 
wrinkles
Phase II completed (2013)
AZX-100 PTD4 Heat shock protein 20 Scar prevention and 
scar reduction
Phase II completed (2012)
KAI-9803 Tat(47–57) Protein kinase Cδ inhibitor Myocardial infarction Phase II completed (2011)
KAI-1678 Tat(47–57) Protein kinase Cδ inhibitor Spinal cord injury Phase II completed (2011)
AVI-5038 Unknown Antisense PMO Duchene muscular 
dystrophy
Preclinical (2012)
XG-102 Tat(48–57) C-Jun-N-terminal kinases Inflammation Phase I completed (2012)
p28 p28 Also p28, a non-HDM2-me-
diated peptide inhibitor of 
p53 ubiquitination
Refractory solid tumors Phase I completed (2013)
AM111 Tat(48–57) Inhibitor of C-Jun-N- 
-terminal kinases
Hearing loss Phase II completed (2013)
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Conclusions
The unique properties and the wide range of appli-
cations of cell-penetrating peptides have made this 
group of compounds one of the most widely studied 
over the past 25 years. The first discovered CPPs, 
such as Tat and penetratin, are still being studied as 
efficient cargo delivery CPPs. Despite the enormous 
progress in the designing and synthesis of new drugs, 
still most of them are not satisfactorily effective in 
vivo. The penetrating properties of CPPs increase 
the efficiency of the delivery of hydrophilic drugs 
and genetic material into many cell types (including 
brain cells) in vivo. This may lead to advances in the 
treatment of diseases for which, due to difficulties 
in drug delivery system, no effective treatment is 
available. However, before the CPPs could be used 
as drug carriers, the mechanisms of their cell mem-
brane penetration capability as well as the efficiency, 
selectivity, and cost of synthesis of CPP-cargo hybrids, 
and above all the impact (toxicity) of CPP on living 
organisms should be carefully evaluated.
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